Personalis (PSNL) Stock Price, News & Analysis

Company Overview

Personalis, Inc. is a genomics company focused on precision oncology and advanced genetic testing. The company develops and commercializes molecular diagnostic products designed to help identify cancer-related genomic changes, monitor disease progression and support treatment decisions.

Its product portfolio includes the NeXT platform, which is used to analyze tumor and blood samples. Offerings have included tissue-based profiling, liquid biopsy testing and personalized minimal residual disease monitoring intended to detect small amounts of cancer remaining after treatment or to identify signs of recurrence. Personalis also provides genomic analysis and testing services for biopharmaceutical companies developing cancer therapies and conducting clinical trials.

Founded in 2011 and headquartered in Fremont, California, Personalis initially provided large-scale genomic sequencing and analysis services before focusing more heavily on oncology. The company serves pharmaceutical and biotechnology customers, healthcare organizations and research partners, with testing and genomic services available through collaborations and clinical programs in the United States and other markets.

Key Stats

• Today's Range: $16.22 to $16.44
• 50-Day Range: $11.73 to $18.38
• 52-Week Range: $4.95 to $18.89
• Volume: 332,270 shs
• Average Volume: 2.63 million shs
• Market Capitalization: $1.70 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.54
• Consensus Rating: Hold

Personalis Stock Analysis - MarketRank™

Personalis scored higher than 32% of companies evaluated by MarketBeat, and ranked 726th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Personalis has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on no strong buy ratings, 4 buy ratings, 5 hold ratings, and 1 sell rating.

Downside Risk

Personalis has a consensus price target of $14.54, representing about 10.1% downside from its current price of $16.17.

Amount of Analyst Coverage

Personalis has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Personalis are expected to grow in the coming year, from ($1.07) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Personalis is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Personalis is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Personalis has a P/B Ratio of 5.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.24% of the float of Personalis has been sold short.

Short Interest Ratio / Days to Cover

Personalis has a short interest ratio ("days to cover") of 3.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Personalis has recently decreased by 1.41%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Personalis does not currently pay a dividend.

Dividend Growth

Personalis does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.06

News Sentiment

Personalis has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Personalis this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for PSNL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

7 people have added Personalis to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,774,916.00 in company stock.

Percentage Held by Insiders

4.20% of the stock of Personalis is held by insiders.

Percentage Held by Institutions

61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:PSNL
• CIK: 1527753
• Web: www.personalis.com
• Phone: (650) 752-1300
• Fax: N/A
• Employees: 260
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Personalis: $14.54
• High Price Target: $17.00
• Low Price Target: $10.00
• Potential Upside/Downside: -10.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.27 million
• Net Margins: -153.84%
• Pretax Margin: -153.79%
• Return on Equity: -46.47%
• Return on Assets: -35.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.28
• Quick Ratio: 5.08

Sales & Book Value

• Annual Sales: $69.65 million
• Price / Sales: 24.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.94 per share
• Price / Book: 5.52

Miscellaneous

• Outstanding Shares: 104,720,000
• Free Float: 100,323,000
• Market Cap: $1.70 billion
• Optionable: Optionable
• Beta: 2.32